Recurrence rates associated with incompletely excised, low-risk nonmelanoma skin cancer - 24/04/13
Doi : 10.1016/j.jaad.2009.11.417
Il testo completo di questo articolo è disponibile in PDF.
Kerri Rieger, MD, PhD, Stanford University Medical Center, Department of Dermatology, Redwood City, CA, United States; Barbara Egbert, MD, Pathology Services, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, United States; Eleni Linos, MD, PhD, Stanford University Medical Center, Department of Dermatology, Redwood City, CA, United States; Susan Swetter, MD, Dermatology Services, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, United States
Il testo completo di questo articolo è disponibile in PDF.| Commercial support: None identified. |
© 2010
American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 62 - N° 3S1
P. AB106 - marzo 2010 Ritorno al numero
Articolo precedente
- Multicenter, randomized, double-blind, vehicle-controlled, dose-ranging study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel 0.005%, 0.01%, and 0.015% when used to treat actinic keratoses on the head
- Multicenter, open-label, dose-area escalation, cohort study to evaluate the safety and tolerability of PEP005 (ingenol mebutate) gel 0.05% applied for two consecutive days to treatment area(s) of up to a total of 100cm2 in patients with actinic keratoses
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?